Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 2009
PURPOSE: To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. METHODS: The melanoma staging recommendations were made on the basis of a multivariate analysis of 30,946 patients with stages I, II, and III melanoma and 7,972 patients with stage IV melanoma to revise and clarify TNM classifications and stage grouping criteria. RESULTS: Findings and new definitions include the following: (1) in patients with localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), and ulceration were the most dominant prognostic factors. (2) Mitotic rate replaces level of invasion as a primary criterion for defining T1b melanomas. (3) Among the 3,307 patients with regional metastases, components that defined the N category were the number of metastatic nodes, tumor burden, and ulceration of the primary melanoma. (4) For staging purposes, all patients with microscopic nodal metastases, regardless of extent of tumor burden, are classified as stage III. Micrometastases detected by immunohistochemistry are specifically included. (5) On the basis of a multivariate analysis of patients with distant metastases, the two dominant components in defining the M category continue to be the site of distant metastases (nonvisceral v lung v all other visceral metastatic sites) and an elevated serum lactate dehydrogenase level. CONCLUSION: Using an evidence-based approach, revisions to the AJCC melanoma staging system have been made that reflect our improved understanding of this disease. These revisions will be formally incorporated into the seventh edition (2009) of the AJCC Cancer Staging Manual and implemented by early 2010.
Cited by 4,602 works. doi:10.1200/jco.2009.23.4799
Authors
- Charles M. Balch
- Jeffrey E. Gershenwald
- Seng-Jaw Soong
- John F. Thompson
- Michael B. Atkins
- David R. Byrd
- Antonio Carlos Buzaid
- Alistair J. Cochran
- Daniel G. Coit
- Shouluan Ding
- Alexander M.M. Eggermont
- Keith T. Flaherty
- Phyllis A. Gimotty
- John M. Kirkwood
- Kelly M. McMasters
- Martín C. Mihm
- Donald L. Morton
- Merrick I. Ross
- Arthur J. Sober
- Vernon K. Sondak
References
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
- Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients
- Prognostic factors in 1,521 melanoma patients with distant metastases.
- A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
- Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
- Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.
- Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials
- Sentinel Lymph Node Biopsy in Cutaneous Melanoma: The WHO Melanoma Program Experience
- Immunohistochemical characteristics of melanoma